Follow
Louise R. Howe
Louise R. Howe
Program Director, National Science Foundation
Verified email at nsf.gov
Title
Cited by
Cited by
Year
Activation of the MAP kinase pathway by the protein kinase raf
LR Howe, SJ Leevers, N Gómez, S Nakielny, P Cohen, CJ Marshall
Cell 71 (2), 335-342, 1992
10141992
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
AJ Dannenberg, NK Altorki, JO Boyle, C Dang, LR Howe, BB Weksler, ...
The lancet oncology 2 (9), 544-551, 2001
8182001
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
LR Howe, K Subbaramaiah, AM Brown, AJ Dannenberg
Endocrine-related cancer 8 (2), 97-114, 2001
4562001
Wnt signaling and breast cancer
LR Howe, AMC Brown
Cancer Biology and Therapy 3 (1), 36-41, 2004
4542004
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
LR Howe
Breast Cancer Research 9 (4), 210, 2007
3972007
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer
LR Howe, K Subbaramaiah, CA Hudis, AJ Dannenberg
Clinical Cancer Research 19 (22), 6074-6083, 2013
3672013
Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation
LR Howe, O Watanabe, J Leonard, AMC Brown
Cancer research 63 (8), 1906-1913, 2003
3132003
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1.
LR Howe, CJ Marshall
Journal of Biological Chemistry 268 (28), 20717-20720, 1993
3021993
Transcriptional Activation of Cyclooxygenase-2in Wnt-1-transformed Mouse Mammary Epithelial Cells
LR Howe, K Subbaramaiah, WJ Chung, AJ Dannenberg, AMC Brown
Cancer research 59 (7), 1572-1577, 1999
2631999
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer
LR Howe, K Subbaramaiah, J Patel, JL Masferrer, A Deora, C Hudis, ...
Cancer research 62 (19), 5405-5407, 2002
2592002
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice
LR Howe, SH Chang, KC Tolle, R Dillon, LJT Young, RD Cardiff, ...
Cancer research 65 (21), 10113-10119, 2005
2002005
A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras.
D Schaap, J van der Wal, LR Howe, CJ Marshall, WJ van Blitterswijk
Journal of Biological Chemistry 268 (27), 20232-20236, 1993
1941993
A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer
LR Howe, AJ Dannenberg
Seminars in oncology 29 (3), 111-119, 2002
1872002
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
NM Iyengar, XK Zhou, A Gucalp, PG Morris, LR Howe, DD Giri, M Morrow, ...
Clinical Cancer Research 22 (9), 2283-2289, 2016
1862016
PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2
LR Howe, HC Crawford, K Subbaramaiah, JA Hassell, AJ Dannenberg, ...
Journal of Biological Chemistry 276 (23), 20108-20115, 2001
1692001
Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize β-catenin independently of Frizzled proteins
K Brennan, JM Gonzalez-Sancho, LA Castelo-Soccio, LR Howe, ...
Oncogene 23 (28), 4873-4884, 2004
1312004
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target
JL McElwee, S Mohanan, OL Griffith, HC Breuer, LJ Anguish, ...
BMC cancer 12 (1), 500, 2012
1252012
Multiple kinases mediate T-cell-receptor signalling
LR Howe, A Weiss
Trends in biochemical sciences 20 (2), 59-64, 1995
1201995
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism
K Subbaramaiah, LR Howe, ER Port, E Brogi, J Fishman, CH Liu, T Hla, ...
Cancer research 66 (10), 5504-5511, 2006
1182006
Targeting the HER/EGFR/ErbB family to prevent breast cancer
LR Howe, PH Brown
Cancer prevention research 4 (8), 1149-1157, 2011
1112011
The system can't perform the operation now. Try again later.
Articles 1–20